Clinical potential of antibody-drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Antibody-drug conjugates (ADCs) show superior response rates and progression-free survival in late-line cancer trials compared to comprehensive genomic profiling (CGP)-matched therapy. Early referral to Phase 1 trials is crucial for optimal outcomes.
Area Of Science
- Oncology
- Clinical Trials
- Genomic Medicine
Background
- Comprehensive genomic profiling (CGP)-matched therapy and antibody-drug conjugates (ADCs) are gaining traction.
- Their efficacy in early-phase, late-line clinical trials requires further elucidation.
Purpose Of The Study
- To evaluate clinical outcomes of CGP-matched therapy versus ADCs in advanced solid tumors treated in late-line clinical trials.
- To identify prognostic factors influencing treatment response.
Main Methods
- Retrospective chart review of 173 patients with advanced solid tumors in late-line trials (Jan 2020-Dec 2023).
- Comparison of overall response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) between treatment groups.
Main Results
- ADCs demonstrated the highest ORR (31.9%) and DCR (68.1%).
- ADCs showed significantly longer median PFS (4.0 months) compared to CGP-matched (1.9 months) and other trials (1.7 months).
- Multivariate analysis indicated ADCs improved PFS, while CGP-matched therapy improved OS.
Conclusions
- ADCs enhance therapeutic responses in early-phase, late-line clinical trials for advanced solid tumors.
- Prioritizing early referral to Phase 1 facilities and appropriate patient selection are vital for optimizing outcomes, rather than solely relying on CGP results.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...